Mark Agulnik, MD

Title(s)Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
Address1520 San Pablo St.
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard
    Other Positions
    Title(s)Vice Chair for Faculty Development, Department of Medicine

    Title(s)Section Chief of Sarcomas & Melanoma


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2024 Aug 12. Konda B, Sherman EJ, Massarelli E, Nieva J, Muzaffar J, Morris Iii JC, Ryder M, Ho AL, Agulnik M, Wei L, Handley D, Moses C, Jacob R, Wright J, Streicher H, Carson W, Shah MH. PMID: 39133806.
      View in: PubMed   Mentions: 1     Fields:    
    2. Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report. ESMO Open. 2024 Jul; 9(7):103487. Schöffski P, Jones RL, Agulnik M, Blay JY, Chalmers A, Italiano A, Pink D, Stacchiotti S, Valverde C, Vincenzi B, Wagner MJ, Maki R. PMID: 38943735; PMCID: PMC11261277.
      View in: PubMed   Mentions: Translation:Humans
    3. Prices and Trends in FDA-Approved Medications for Sarcomas. Cancers (Basel). 2024 Apr 18; 16(8). Hwang C, Agulnik M, Schulte B. PMID: 38672627; PMCID: PMC11048328.
      View in: PubMed   Mentions:
    4. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13; 403(10435):1460-1471. D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. PMID: 38554725; PMCID: PMC11419333.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    5. Diffuse intra-abdominal sarcomatosis in myxoid pleomorphic liposarcoma. BMJ Case Rep. 2024 Jan 16; 17(1). Tseng WW, Liang Y, Nguyen B, Agulnik M, Creytens D. PMID: 38232999; PMCID: PMC10806920.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. SMARCA4 / BRG1 -deficient Uterine Neoplasm With Hybrid Adenosarcoma and Carcinoma Features: Expanding the Molecular-morphologic Spectrum of SMARCA4 -driven Gynecologic Malignancies. Int J Gynecol Pathol. 2024 Jul 01; 43(4):354-361. Wei CH, Sadimin E, Agulnik M, Yost SE, Longacre TA, Fadare O. PMID: 38113031; PMCID: PMC11166733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma. J Pers Med. 2023 Oct 15; 13(10). Rock A, Uche A, Yoon J, Agulnik M, Chow W, Millis S. PMID: 37888109; PMCID: PMC10608227.
      View in: PubMed   Mentions:
    8. Underreporting of SMARCB1 alteration by clinical sequencing: Integrative patho-genomic analysis captured SMARCB1/INI-1 deficiency in a vulvar yolk sac tumor. Gynecol Oncol Rep. 2023 Dec; 50:101294. Wei CH, Wang E, Sadimin E, Rodriguez-Rodriguez L, Agulnik M, Yoon J, LoBello J, Szelinger S, Anderson C. PMID: 37876879; PMCID: PMC10590733.
      View in: PubMed   Mentions:
    9. State of Cancer Care in America: Achieving Cancer Health Equity Among Sexual and Gender Minority Communities. JCO Oncol Pract. 2023 11; 19(11):959-966. Kamen CS, Dizon DS, Fung C, Pratt-Chapman ML, Agulnik M, Fashoyin-Aje LA, Jeames SE, Merrill JK, Smith KT, Maingi S. PMID: 37793079.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Role of immunotherapy in chondrosarcoma: A case report and review of the literature. Ther Adv Med Oncol. 2023; 15:17588359231199877. Cohen-Nowak AJ, Dressler DB, Rock A, Mojica K, Woo D, Zuckerman LM, Chow W, Agulnik M. PMID: 37745839; PMCID: PMC10515522.
      View in: PubMed   Mentions: 2  
    11. Implications of updated staging system for p16+ oropharyngeal squamous cell carcinoma: Is valuable prognostic information being omitted? Head Neck. 2023 08; 45(8):2079-2086. Vo K, Ladbury C, Tam A, Maghami E, Kang R, Villaflor V, Agulnik M, Gernon T, Glaser S, Amini A. PMID: 37345637.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Surgical Management of Retroperitoneal Sarcoma. Curr Oncol. 2023 04 29; 30(5):4618-4631. Dominguez DA, Sampath S, Agulnik M, Liang Y, Nguyen B, Trisal V, Melstrom LG, Lewis AG, Paz IB, Roberts RF, Tseng WW. PMID: 37232807; PMCID: PMC10217420.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma. J Clin Med. 2023 Mar 29; 12(7). Heater NK, Okuno S, Robinson S, Attia S, Seetharam M, Siontis BL, Yoon J, Chawla S, Milhem MM, Monga V, Skubitz K, Charlson J, Hirbe AC, Weiss MC, Van Tine B, Agulnik M. PMID: 37048645; PMCID: PMC10095464.
      View in: PubMed   Mentions: 1  
    14. Targeted therapies for the treatment of soft tissue sarcoma. Front Oncol. 2023; 13:1122508. Fuchs JW, Schulte BC, Fuchs JR, Agulnik M. PMID: 36969064; PMCID: PMC10034045.
      View in: PubMed   Mentions: 5  
    15. Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma. Front Oncol. 2023; 13:1123464. Fuchs JR, Schulte BC, Fuchs JW, Agulnik M. PMID: 36761952; PMCID: PMC9905840.
      View in: PubMed   Mentions: 2  
    16. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw. 2022 11; 20(11):1204-1214. von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Poppe M, Schuetze S, Shabason J, Spraker MB, Zimel M, Bergman MA, Sundar H, Hang LE. PMID: 36351335; PMCID: PMC10245542.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    17. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163. Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. PMID: 36215947; PMCID: PMC10204709.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    18. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 2023 01; 12(2):1532-1539. Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW, Maki RG. PMID: 35950293; PMCID: PMC9883574.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    19. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522. Thiebaud JA, Ravi V, Litwin S, Schuetze SM, Movva S, Agulnik M, Kraft AS, Tetzlaff ED, Somaiah N, von Mehren M. PMID: 35942596; PMCID: PMC9616178.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    20. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 07; 20(7):815-833. von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA. PMID: 35830886; PMCID: PMC10186762.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    21. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022 06 15; 13(1):3406. Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. PMID: 35705558; PMCID: PMC9200814.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    22. Evolving strategies for management of desmoid tumor. Cancer. 2022 08 15; 128(16):3027-3040. Riedel RF, Agulnik M. PMID: 35670122; PMCID: PMC9546183.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    23. All-Internal Limb Lengthening with Simultaneous Corrective Osteotomy After Internal Hemipelvectomy: A Case Report. JBJS Case Connect. 2022 04 01; 12(2). Femino JD, Nelson SC, Agulnik M, Zuckerman LM. PMID: 36099533.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. Cancer Med. 2022 09; 11(18):3471-3478. Miller D, Livingston JA, Park Y, Posey K, Godbole S, Skubitz K, Robinson SI, Agulnik M, Davis LE, Van Tine BA, Hirbe AC, Parkes A. PMID: 35343652; PMCID: PMC9487868.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10). Health Sci Rep. 2021 Dec; 4(4):e401. Shaunfield S, Yount SE, Boyken L, Agulnik M, Samant S, Cella D. PMID: 34708159; PMCID: PMC8525466.
      View in: PubMed   Mentions: 3  
    26. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021 08; 9(8). Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, Budd GT, Victor AI, Hsueh CT, Chugh R, Nair S, Leu KM, Agulnik M, Sharon E, Mayerson E, Plets M, Blanke C, Streicher H, Chae YK, Kurzrock R. PMID: 34380663; PMCID: PMC8330584.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    27. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021 09; 154:201-208. Agulnik M, Schulte B, Robinson S, Hirbe AC, Kozak K, Chawla SP, Attia S, Rademaker A, Zhang H, Abbinanti S, Cehic R, Monga V, Milhem M, Okuno S, Van Tine BA. PMID: 34284255.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    28. The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. Front Oncol. 2021; 11:649963. Pharaon RR, Xing Y, Agulnik M, Villaflor VM. PMID: 34336649; PMCID: PMC8322686.
      View in: PubMed   Mentions: 2  
    29. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2022 04 20; 40(12):1291-1300. Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. PMID: 34260265.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    30. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer. 2021 08; 125(4):528-533. Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M. PMID: 34050255; PMCID: PMC8368095.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    31. Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report. Oncologist. 2021 07; 26(7):549-553. Lambden JP, Kelsten MF, Schulte BC, Abbinanti S, Hayes JP, Villaflor V, Agulnik M. PMID: 33594725; PMCID: PMC8265341.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    32. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432. Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. PMID: 33035459.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansCTClinical Trials
    33. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020 09; 137:1-9. Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem M, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA. PMID: 32712457.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    34. A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. Cancers (Basel). 2020 Jul 11; 12(7). Monga V, Skubitz KM, Maliske S, Mott SL, Dietz H, Hirbe AC, Van Tine BA, Oppelt P, Okuno S, Robinson S, O'Connor M, Seetharam M, Attia S, Charlson J, Agulnik M, Milhem M. PMID: 32664595; PMCID: PMC7408640.
      View in: PubMed   Mentions: 24  
    35. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. Cancer Med. 2020 02; 9(3):882-893. Villalobos VM, Mo G, Agulnik M, Pollack SM, Rushing DA, Singh A, Van Tine BA, McNaughton R, Decker RL, Zhang W, Shahir A, Cronier DM. PMID: 31821732; PMCID: PMC6997100.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    36. Elemental Zn and its Binding Protein Zinc-α2-Glycoprotein are Elevated in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Sci Rep. 2019 11 18; 9(1):16965. Poropatich K, Paunesku T, Zander A, Wray B, Schipma M, Dalal P, Agulnik M, Chen S, Lai B, Antipova O, Maxey E, Brown K, Wanzer MB, Gursel D, Fan H, Rademaker A, Woloschak GE, Mittal BB. PMID: 31740720; PMCID: PMC6861298.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    37. Ectopic hamartomatous thymoma in an immunocompromised male. Pathol Res Pract. 2019 Sep; 215(9):152497. Waters D, Obeidin F, Alexiev BA, Rao MS, Peabody TD, Agulnik M, Yeldandi A. PMID: 31257088.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 06 01; 37(16):1424-1431. Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. PMID: 31013172; PMCID: PMC7799443.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    39. A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma. Cancer Med. 2019 06; 8(6):2994-3003. Van Tine BA, Agulnik M, Olson RD, Walsh GM, Klausner A, Frank NE, Talley TT, Milhem MM. PMID: 31016866; PMCID: PMC6558450.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    40. Piloting a Financial Counseling Intervention for Patients With Cancer Receiving Chemotherapy. J Oncol Pract. 2019 03; 15(3):e202-e210. Kircher SM, Yarber J, Rutsohn J, Guevara Y, Lyleroehr M, Alphs Jackson H, Walradt J, Desai B, Mulcahy M, Kalyan A, Benson AB, Agulnik M, Mohindra N, DeSouza J, Garcia SF. PMID: 30625023.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    41. Growing Role of Regorafenib in the Treatment of Patients with Sarcoma. Target Oncol. 2018 08; 13(4):417-422. Agulnik M, Attia S. PMID: 29931504.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. Oncotarget. 2018 Jun 15; 9(46):28281-28289. Chae YK, Chiec L, Adney SK, Waitzman J, Costa R, Carneiro B, Matsangou M, Agulnik M, Kopp P, Giles F. PMID: 29963277; PMCID: PMC6021337.
      View in: PubMed   Mentions: 7     Fields:    
    43. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 05 10; 36(14):1412-1418. Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. PMID: 29584545; PMCID: PMC5941615.
      View in: PubMed   Mentions: 215     Fields:    Translation:HumansCTClinical Trials
    44. Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment. Curr Treat Options Oncol. 2018 03 15; 19(4):19. Rosenberg A, Agulnik M. PMID: 29546487.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    45. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. PMID: 28651927; PMCID: PMC7771354.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCTClinical Trials
    46. Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. J Neurooncol. 2017 Aug; 134(1):197-203. Patel RA, Bell JB, Kim T, Agulnik M, Chandler JP, Mittal BB, Kruser TJ. PMID: 28547589.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. Olaratumab for advanced soft tissue sarcoma. Expert Rev Clin Pharmacol. 2017 Jul; 10(7):699-705. Tobias A, O'brien MP, Agulnik M. PMID: 28447475.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    48. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. Drugs. 2017 May; 77(8):843-857. Moreira J, Tobias A, O'Brien MP, Agulnik M. PMID: 28382569.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    49. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017 02; 15(2):155-167. Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry SV, Million L, Morris CD, Movva S, O'Donnell RJ, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL. PMID: 28188186.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    50. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Jan 31; 8(5):8910-8920. Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. PMID: 27852042; PMCID: PMC5352453.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    51. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2017 01 01; 28(1):121-127. Agulnik M, Costa RLB, Milhem M, Rademaker AW, Prunder BC, Daniels D, Rhodes BT, Humphreys C, Abbinanti S, Nye L, Cehic R, Polish A, Vintilescu C, McFarland T, Skubitz K, Robinson S, Okuno S, Van Tine BA. PMID: 27771610; PMCID: PMC6246191.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    52. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905. Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PMID: 27621408.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    53. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol. 2016 10; 27(10):1855-60. Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK. PMID: 27502708; PMCID: PMC5035789.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    54. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK. PMID: 27291997; PMCID: PMC5647653.
      View in: PubMed   Mentions: 247     Fields:    Translation:HumansCTClinical Trials
    55. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. Eur J Cancer. 2016 07; 61:94-101. Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H. PMID: 27156227.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    56. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther. 2016; 10:873-84. Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ. PMID: 27013865; PMCID: PMC4778792.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    57. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma. Am J Clin Oncol. 2015 Dec; 38(6):588-94. Refaat T, Choi M, Thomas TO, Bacchus I, Agulnik M, Pelzer HJ, Mellott AL, Rademaker AW, Liu D, Sathiaseelan V, Mittal BB. PMID: 24136140; PMCID: PMC4713122.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    58. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist. 2015 Nov; 20(11):1245-6. Munhoz RR, D'Angelo SP, Gounder MM, Keohan ML, Chi P, Carvajal RD, Singer S, Crago AM, Landa J, Healey JH, Qin LX, Hameed M, Ezeoke MO, Singh AS, Agulnik M, Chmielowski B, Luke JJ, Van Tine BA, Schwartz GK, Tap WD, Dickson MA. PMID: 26449382; PMCID: PMC4718433.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    59. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas. Expert Opin Investig Drugs. 2015; 24(11):1409-18. Mohindra N, Agulnik M. PMID: 26289790.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    60. Targeted therapies in advanced differentiated thyroid cancer. Cancer Treat Rev. 2015 Sep; 41(8):690-8. Carneiro RM, Carneiro BA, Agulnik M, Kopp PA, Giles FJ. PMID: 26105190.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    61. Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor. Am J Clin Oncol. 2014 Aug; 37(4):417-22. Agulnik M, Giel JL. PMID: 22772433.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    62. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. PMID: 25049329; PMCID: PMC4876357.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansCTClinical Trials
    63. Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Thyroid. 2014 Sep; 24(9):1329-40. Lacouture ME, Ciccolini K, Kloos RT, Agulnik M. PMID: 24902006; PMCID: PMC4148058.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    64. Occult primary, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):969-74. Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA, National Comprehensive Cancer Network. PMID: 24994917.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    65. Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma. J Surg Oncol. 2014 Nov; 110(6):682-8. Sherman KL, Kinnier CV, Farina DA, Wayne JD, Laskin WB, Agulnik M, Attar S, Hayes JP, Peabody T, Bilimoria KY. PMID: 24910401.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    66. Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: a pilot study. Head Neck. 2015 Apr; 37(4):567-72. Mittal BB, Pauloski BR, Rademaker AW, Discekici-Harris M, Helenowski IB, Mellot A, Agulnik M, Logemann JA. PMID: 24677442; PMCID: PMC4139482.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    67. Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. Onco Targets Ther. 2014; 7:245-51. Gandhi MD, Agulnik M. PMID: 24611017; PMCID: PMC3928467.
      View in: PubMed   Mentions: 3  
    68. Assessment of multimodality therapy use for extremity sarcoma in the United States. J Surg Oncol. 2014 Apr; 109(5):395-404. Sherman KL, Wayne JD, Chung J, Agulnik M, Attar S, Hayes JP, Laskin WB, Peabody TD, Bentrem DJ, Pollock RE, Bilimoria KY. PMID: 24375444.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    69. Effect of recombinant human deoxyribonuclease on oropharyngeal secretions in patients with head-and-neck cancers treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):282-9. Mittal BB, Wang E, Sejpal S, Agulnik M, Mittal A, Harris K. PMID: 23910712.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    70. Bone cancer. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):688-723. Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, von Mehren M, Bergman MA, Sundar H, National complrehensive cancer network. PMID: 23744868.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    71. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. PMID: 23477833; PMCID: PMC3766955.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCTClinical Trials
    72. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013; 6:135-43. Nelson V, Ziehr J, Agulnik M, Johnson M. PMID: 23493883; PMCID: PMC3594037.
      View in: PubMed   Mentions: 43  
    73. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013 Mar; 73(4):315-25. Dorsey K, Agulnik M. PMID: 23440867.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    74. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan; 24(1):257-63. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. PMID: 22910841.
      View in: PubMed   Mentions: 168     Fields:    Translation:HumansCTClinical Trials
    75. Advances in adjuvant therapy of gastrointestinal stromal tumors. Curr Oncol Rep. 2012 Aug; 14(4):327-32. Adekola K, Agulnik M. PMID: 22535506.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    76. A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma. Invest New Drugs. 2013 Feb; 31(1):145-51. Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R, Keohan ML. PMID: 22539091.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    77. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE. PMID: 22513208.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    78. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib. Chemotherapy. 2012; 58(1):30-3. Svetlichnaya J, Huyck TK, Wayne JD, Agulnik M. PMID: 22415035; PMCID: PMC7065395.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    79. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 2012 Dec; 29(4):2481-91. Agulnik M. PMID: 22252310; PMCID: PMC3466428.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    80. NCCN Clinical Practice Guidelines Occult primary. J Natl Compr Canc Netw. 2011 Dec; 9(12):1358-95. Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK, National Comprehensive Cancer Network. PMID: 22157556.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    81. Management of neuroendocrine tumors of unknown origin. J Natl Compr Canc Netw. 2011 Dec; 9(12):1397-402; quiz 1403. Polish A, Vergo MT, Agulnik M. PMID: 22157557.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    82. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer. 2012 Mar 15; 118(6):1486-97. Agulnik M. PMID: 21837674; PMCID: PMC3412949.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    83. Targeted therapies in bone sarcomas: current approach and future directions. Expert Opin Investig Drugs. 2011 Jul; 20(7):973-9. Yarber JL, Agulnik M. PMID: 21510829.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    84. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011 Jun; 47(6):441-8. Watters AL, Epstein JB, Agulnik M. PMID: 21514211.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    85. Head and neck cancer: changing epidemiology and public health implications. Oncology (Williston Park). 2010 Sep; 24(10):915-9, 924. Kim L, King T, Agulnik M. PMID: 21138172.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsPHPublic Health
    86. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist. 2010; 15(8):810-8. Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard KI, Leighl NB. PMID: 20682606; PMCID: PMC3228026.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    87. Treatment of multiple keratoacanthomas with erlotinib. Int J Clin Oncol. 2010 Aug; 15(4):413-5. Reid DC, Guitart J, Agulnik M, Lacouture ME. PMID: 20221661.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    88. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53. Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME. PMID: 20007525.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    89. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck. 2009 Aug; 31(8):1006-12. Vidal L, Tsao MS, Pond GR, Cohen EE, Cohen RB, Chen EX, Agulnik M, Hotte S, Winquist E, Laurie S, Hayes DN, Ho J, Dancey J, Siu LL. PMID: 19309723; PMCID: PMC2711990.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    90. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer. 2009 Mar 15; 115(6):1286-99. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. PMID: 19170238.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    91. Occult primary. J Natl Compr Canc Netw. 2008 Nov; 6(10):1026-60. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. PMID: 19176200.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    92. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008 Sep 15; 113(6):1446-52. Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL. PMID: 18683883.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansPHPublic Health
    93. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008 Aug; 6(7):696-706. Brockstein B, Lacouture M, Agulnik M. PMID: 18691458.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    94. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008 Jun; 35(3):309-19. Surakanti SG, Agulnik M. PMID: 18544445.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    95. Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions. Expert Opin Ther Targets. 2008 Feb; 12(2):197-207. Aranha O, Agulnik M. PMID: 18208368.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    96. New therapeutic options in gastrointestinal stromal tumors. Oncology (Williston Park). 2008 Feb; 22(2):206-11; discussion 215-6, 219. Stein E, Aranha O, Agulnik M. PMID: 18409663.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    97. Promising newer molecular-targeted therapies in head and neck cancer. Drugs. 2008; 68(12):1609-19. Wang LX, Agulnik M. PMID: 18681486.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    98. Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol. 2008 Jul; 44(7):617-27. Agulnik M, Epstein JB. PMID: 18061518.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansPHPublic Health
    99. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007 Sep 01; 25(25):3978-84. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL. PMID: 17761983.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    100. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007 Aug 20; 25(24):3766-73. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX. PMID: 17704426.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    101. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol. 2007 Jun 01; 25(16):2184-90. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS. PMID: 17538163.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    102. Malignancies of the head and neck: the role for molecular targeted agents. Expert Opin Ther Targets. 2007 Feb; 11(2):207-17. Agulnik M. PMID: 17227235.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    103. The changing management of low-grade astrocytomas and oligodendrogliomas. Hematol Oncol Clin North Am. 2006 Dec; 20(6):1249-66. Agulnik M, Mason WP. PMID: 17113461.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    104. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol. 2006 Oct 20; 24(30):4801-7. Agulnik M, Oza AM, Pond GR, Siu LL. PMID: 17050865.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    105. Recent advances in the treatment of oligodendrogliomas. Curr Neurol Neurosci Rep. 2006 May; 6(3):212-7. Agulnik M, Mason WP. PMID: 16635430.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    106. Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA. Expert Opin Pharmacother. 2006 Mar; 7(4):489-94. Agulnik M, Siu LL. PMID: 16503821.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer. J Chemother. 2005 Apr; 17(2):237-41. Agulnik M, Rhee EN, Yao M, Mundt AJ, Feldman LE. PMID: 15920912.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    108. State-of-the-art management of nasopharyngeal carcinoma: current and future directions. Br J Cancer. 2005 Mar 14; 92(5):799-806. Agulnik M, Siu LL. PMID: 15756250; PMCID: PMC2361911.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    109. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. Curr Med Chem Anticancer Agents. 2004 Nov; 4(6):543-51. Agulnik M, Siu LL. PMID: 15579019.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    110. Integrative tumor board: colon cancer with liver metastases: case presentation. Integr Cancer Ther. 2003 Jun; 2(2):166-198. Schmaltz JR, Agulnik M, Mullane MR, De La Torre M, Block KI, Robertson S, Dixon SW, Broffman M, McCulloch M, Gao J, Perlman MI, Hurst CV. PMID: 15035907.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Malignant lymphoma of mucosa-associated lymphoid tissue of the lacrimal gland: case report and review of literature. Am J Clin Oncol. 2001 Feb; 24(1):67-70. Agulnik M, Tsang R, Baker MA, Kazdan MS, Fernandes B. PMID: 11232953.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    112. Resource utilization for peritoneal catheter placement. ASAIO J. 2001 Jan-Feb; 47(1):97-8. Agulnik M, Hirsch DJ. PMID: 11199325.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    Mark's Networks
    Concepts (330)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (19)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.